| Business Summary | | Aventis
S.A.
is
a
world
leader
in
life
sciences.
Focused
on
two
core
business
areas
-
pharmaceuticals
and
agriculture
-
Aventis
is
dedicated
to
improving
life
through
the
discovery
and
development
of
innovative
products
in
the
fields
of
prescription
drugs,
vaccines,
therapeutic
proteins,
crop
production
and
protection,
animal
health
and
nutrition.
With
global
corporate
headquarters
in
Strasbourg,
France,
Aventis
employs
around
95,000
people
in
more
than
120
countries.
Aventis
was
launched
in
December
1999
through
the
merger
of
Hoechst
AG
of
Germany
and
Rhone-Poulenc
S.A
of
France. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Aventis
is
engaged
in
the
research,
development,
production,
marketing
and
sale
of
organic
and
inorganic
intermediate
chemicals,
specialty
chemicals,
fibers,
polymers,
pharmaceuticals
and
agricultural
chemicals.
For
the
six
months
ended
6/01,
net
sales
rose
5%
to
EUR11.65
billion.
Net
income
applicable
to
Common
before
U.S.
GAAP
totalled
EUR730M,
up
from
EUR337M.
Results
reflect
increased
sales
of
prescription
drugs,
and
decreased
restructuring
costs. | More
from
Market Guide: Significant
Developments |
| Officers | |
| Position | Jurgen Dormann | Chairman
of Management | Jean-Rene Fourtou, 59 | Vice
Chairman of Management | Igor Landau, 54 | Member
of the Board of Management | Horst Waesche | Member
of the Board of Management | Patrick Langlois, 53 | Group
Exec. VP, CFO |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|